Narcolepsy News and Research

RSS

Narcolepsy is a chronic sleep disorder, or dyssomnia. The condition is characterized by excessive daytime sleepiness (EDS) in which a person experiences extreme fatigue and possibly falls asleep at inappropriate times, such as while at work or at school.

New Sleep and Breathing Disorders Center at UT Southwestern

UT Southwestern Medical Center has assembled a comprehensive team of experts in pulmonary medicine, neurology, psychiatry, pediatrics, otolaryngology, surgery and rehabilitation medicine to work together in a new Sleep and Breathing Disorders Center.

10 Jan 2008

Effects of sleep deprivation reversed

Researchers at Wake Forest University School of Medicine have shown that the effects of sleep deprivation on cognitive performance can be reversed when the naturally occurring brain peptide, orexin-A, is administered in monkeys.

3 Jan 2008

Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin

Practice parameters published in the December 1 issue of the journal SLEEP serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, including idiopathic hypersomnia, recurrent hypersomnia and hypersomnia due to medical condition.

3 Dec 2007

Hormone orexin links sleep, hunger and metabolism

While investigating how the hormone orexin might control sleep and hunger, researchers at UT Southwestern Medical Center have discovered, to their surprise, that it activates a protein, HIF-1, long known to stimulate cancerous tumor growth.

15 Nov 2007

FDA warns about 'stay awake drug' Provigil

The U.S. Food and Drug Administration (FDA) has issued a warning in connection with the drug Provigil because of dangerous side effects.

28 Oct 2007

The biomedical and sociological effects of sleep restriction

In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, “The biomedical and sociological effects of sleep restriction”, is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.

22 Oct 2007

Modafinil effective treatment for excessive sleepiness

A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness associated with disorders of sleep and wakefulness such as shift work sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and does not affect cardiovascular or sleep parameters.

16 Oct 2007

Insomniac fish help understand the genetics behind sleep disorders

Scientists at the Stanford University School of Medicine have hooked a fish that suffers from insomnia in their quest to understand the genetics behind sleep disorders.

16 Oct 2007

Lower metabolism, eating behavior possibly explain the cause of overweight in narcolepsy

A lower metabolism, as well as slight changes in eating behavior, could explain the positive energy balance leading to being overweight in narcolepsy, according to a study published in the October 1 issue of the journal SLEEP.

2 Oct 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Modafinil under study for bipolar disorder

A preliminary study of 85 patients with bipolar disorder shows that a drug used to treat patients with sleep disorders might also control the depressive symptoms associated with bipolar disorder.

3 Aug 2007

Persons with narcolepsy with cataplexy have low levels of protein thought to help regulate sleep

Persons with narcolepsy with cataplexy have low levels of cerebrospinal fluid (CSF) hypocretin-1, a protein thought to help regulate sleep and wakefulness, according to a study published in the August 1st issue of the journal SLEEP.

2 Aug 2007

Biological markers of narcolepsy

The first report to identify the biological markers of narcolepsy using gene expression in white blood cells finds that the MX2 gene, which is relevant to the immune system, is significantly less expressed in narcoleptics compared with normal subjects.

2 Aug 2007

People with narcolepsy have a high frequency of REM sleep without muscle atonia

Normal rapid eye movement (REM) sleep is characterized by tonic features, including cortical electroencephalogram (EEG) desynchronization and muscle atonia, as well as phasic events, including bursts of REM, phasic activities of both chin and limb electromyography (EMG), and cardiorespiratory variability.

4 Jul 2007

Sleep disorders common among police officers

Sleep disorders are common, costly and treatable, but often remain undiagnosed and untreated.

16 Jun 2007

Modafinil (Provigil) alleviates post-chemotherapy fogginess

A drug described by some people as a genius pill for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as chemo-brain, according to a University of Rochester Medical Center study.

5 Jun 2007

Wide range of sleep-related disorders associated with abnormal sexual behaviors, experiences

A paper published in the June 1st issue of the journal SLEEP is the first literature review and formal classification of a wide range of documented sleep-related disorders associated with abnormal sexual behaviors and experiences.

3 Jun 2007

Link between Parkinson's and narcolepsy

Parkinson's disease is well-known for its progression of motor disorders: stiffness, slowness, tremors, difficulties walking and talking.

17 May 2007

Modafinil which improves intelligence under scrutiny by Health Department

The British government is examining the impact of a new generation of drugs that are claimed to make people more intelligent.

19 Apr 2007

Cephalon provides update on Nuvigil NDA

Cephalon has announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).

2 Apr 2007